Brolucizumab

Summary

Brolucizumab (CHEMBL3707357) is an approved antibody (ATC S01LA06); indicated across 6 conditions including wet macular degeneration and ocular vascular disorder.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Antibody
• ATC class: S01LA06
• Indications: 6 conditions
• Clinical trials: 42

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL3707357
Name	Brolucizumab
Type	Antibody
Max phase	4
ATC	S01LA06

Also known as: Brolucizumab, Brolucizumab dbll, Brolucizumab-dbll, Beovu, ESBA-1008, ESBA1008, RTH-258, RTH258, BROLUCIZUMAB

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

6 indications (2 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
wet macular degeneration	4	MONDO:0005417	EFO:0004683
ocular vascular disorder	4	MONDO:0005552	EFO:0005753
age-related macular degeneration	3	MONDO:0005150	EFO:0001365
retinal vein occlusion	3	MONDO:0006951	EFO:1001157
choroidal neovascularization	3	MONDO:0810000	MONDO:0810000

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 42.

Phase distribution

Phase	Trials
PHASE3	18
Not specified	13
PHASE4	7
PHASE2	3
PHASE1/PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT04679935	PHASE4	COMPLETED	Efficacy and Safety of Two Different Brolucizumab 6 mg Dosing Regimens in Neovascular Age-related Macular Degeneration
NCT04690062	PHASE4	UNKNOWN	BEOVU in the Treatment of Dystrophy-related Macular Neovascular Degeneration
NCT04698850	PHASE4	WITHDRAWN	Brolucizumab vs. Aflibercept for Retinal Angiomatous Proliferation
NCT04774926	PHASE4	COMPLETED	Study of Innovative Multimodal Imaging Biomarkers to Predict Anatomical Outcome in Naive Patients With wAMD Treated With Brolucizumab.
NCT05269966	PHASE4	COMPLETED	Study to Evaluate the Safety and Effectiveness of Intravitreal Injections (IVI) of Brolucizumab in Patients With Neovascular Age-related Macular Degeneration (nAMD)
NCT05710471	PHASE4	COMPLETED	Treatment of Recalcitrant Neovascular AMD Using Brolocizumab With Immediate T&E
NCT05959304	PHASE4	COMPLETED	Post Marketing Study to Evaluate the Safety and Effectiveness of Brolucizumab in Patients With Diabetic Macular Edema.
NCT03386474	PHASE3	COMPLETED	Study of Safety and Efficacy of Brolucizumab 6 mg Drug Product Intended for Commercialization in Patients With nAMD
NCT03481634	PHASE3	COMPLETED	Study of Efficacy and Safety of Brolucizumab vs. Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema
NCT03481660	PHASE3	COMPLETED	A Study of the Efficacy and Safety of Brolucizumab vs. Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema
NCT03710564	PHASE3	TERMINATED	Study of Safety and Efficacy of Brolucizumab 6 mg Dosed Every 4 Weeks Compared to Aflibercept 2 mg Dosed Every 4 Weeks in Patients With Retinal Fluid Despite Frequent Anti-VEGF Injections
NCT03802630	PHASE3	TERMINATED	Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Patients With Visual Impairment Due to Macular Edema Secondary to Branch Retinal Vein Occlusion
NCT03810313	PHASE3	TERMINATED	Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Patients With Visual Impairment Due to Macular Edema Secondary to Central Retinal Vein Occlusion
NCT03917472	PHASE3	COMPLETED	Efficacy and Safety of Brolucizumab vs Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema
NCT03930641	PHASE3	COMPLETED	Study of the Safety of Brolucizumab 6 mg in Prefilled Syringe in Patients With Neovascular Age Related Macular Degeneration
NCT04005352	PHASE3	COMPLETED	Study to Assess the Efficacy and Safety of Brolucizumab 6mg Compared to Aflibercept 2 mg in a Treat-to-control Regimen (TALON)
NCT04047472	PHASE3	COMPLETED	Study of Efficacy and Safety of Brolucizumab vs. Aflibercept in Chinese Patients With Neovascular Age-Related Macular Degeneration
NCT04058067	PHASE3	COMPLETED	To Compare Brolucizumab to Aflibercept in Chinese Patients With Visual Impairment Due to Diabetic Macular Edema
NCT04079231	PHASE3	WITHDRAWN	Efficacy and Safety of Brolucizumab vs. Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema
NCT04239027	PHASE3	COMPLETED	A Study to Assess the Effects of Brolucizumab in Adult Patients With Neovascular Age Related Macular Degeneration
NCT04264819	PHASE3	COMPLETED	Study of Brolucizumab in Adult Patients With Suboptimal Anatomically Controlled Neovascular Age-related Macular Degeneration
NCT04278417	PHASE3	COMPLETED	Study of Efficacy and Safety of Brolucizumab Versus Panretinal Photocoagulation Laser in Patients With Proliferative Diabetic Retinopathy
NCT04597632	PHASE3	COMPLETED	An Extension Study Assessing the Efficacy and Safety of Brolucizumab in a Treat-to-Control Regimen in Patients With Neovascular Age-related Macular Degeneration Who Have Completed the CRTH258A2303 (TALON) Study
NCT04697953	PHASE3	WITHDRAWN	Efficacy and Safety of Brolucizumab 6mg in a Treat and Extend Regimen in Patients With Neovascular Age-Related Macular Degeneration (nAMD) With Prior Anti-VEGF Exposure (PEREGRINE)
NCT05666804	PHASE3	COMPLETED	Study Assessing the Efficacy and Safety of a Personalized Monotherapy Regimen of Brolucizumab in Patients With Symptomatic Macular Polypoidal Choroidal Vasculopathy
NCT01304693	PHASE1/PHASE2	COMPLETED	ESBA1008 Safety, Tolerability and Effects in Wet Age-Related Macular Degeneration (AMD) Patients
NCT01796964	PHASE2	COMPLETED	Efficacy and Safety Study of ESBA1008 Versus EYLEA®
NCT01849692	PHASE2	COMPLETED	ESBA1008 Microvolume Study
NCT02507388	PHASE2	COMPLETED	Safety and Pharmacokinetics of RTH258 in Subjects With Age-Related Macular Degeneration
NCT04932980	Not specified	ACTIVE_NOT_RECRUITING	Comparison of Rapid Aflibercept and Brolucizumab T&E in wAMD
NCT04985487	Not specified	RECRUITING	Regulatory Post-Marketing Surveillance Study for Brolucizumab
NCT04543331	Not specified	COMPLETED	Observational Study to Evaluate Fluid Resolution and Effectiveness in Patients Receiving Beovu in Neovascular Age-related Macular Degeneration and Visual Impairment Due to Diabetic Macular Edema
NCT04632056	Not specified	COMPLETED	A 52-weeks Observational Study to Evaluate the Safety of Brolucizumab in Patients With nAMD
NCT04662944	Not specified	COMPLETED	A Non-interventional Study to Assess the Influence of Automated Optical Coherence Tomography Image Enrichment With Segmentation Information on Disease Activity Assessment in Patients Treated With Licensed Anti- VEGF Injections
NCT04764656	Not specified	TERMINATED	Observational Study to Evaluate Fluid Resolution and Effectiveness of Brolucizumab for nAMD in Portugal
NCT05037396	Not specified	COMPLETED	Evaluation of Number of Patient Eyes That Remained on or Switched to Anti-VEGF Treatment After Initiation of Broluciumab
NCT05082415	Not specified	COMPLETED	Real-world Evaluation of Brolucizumab for the Treatment of Neovascular (Wet) Age-related Macular Degeneration (AMD) (IRIS Study)
NCT05111743	Not specified	COMPLETED	Real-world Evaluation of Brolucizumab for the Treatment of Neovascular (Wet) Age-related Macular Degeneration (AMD) (Komodo Health)
NCT05112835	Not specified	TERMINATED	Brolucizumab Treatment Experience Study of Patients With nAMD in UK Routine Clinical Practice
NCT05266495	Not specified	TERMINATED	Effectiveness of Brolucizumab in Pre-treated Patients With nAMD in the Real-world Setting

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).